Page last updated: 2024-11-12

degrasyn

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

degrasyn: a JAK2 kinase inhibitor that induces rapid degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11222830
CHEMBL ID1923233
SCHEMBL ID1317674
SCHEMBL ID882501
MeSH IDM0509836

Synonyms (33)

Synonym
HY-13264
degrasyn
(e)-3-(6-bromopyridin-2-yl)-2-cyano-n-[(1s)-1-phenylbutyl]prop-2-enamide
wp 1130
wp-1130
SCHEMBL1317674
(2e)-3-(6-bromopyridin-2-yl)-2-cyano-n-[(1s)-1-phenylbutyl]prop-2-enamide
856243-80-6
WP1130 ,
CHEMBL1923233 ,
CS-0483
(s,e)-3-(6-bromopyridin-2-yl)-2-cyano-n-(1-phenylbutyl)acrylamide
SCHEMBL882501
bdbm50437695
smr004702965
MLS006011196
LIDOPKHSVQTSJY-VMEIHUARSA-N
(2e)-3-(6-bromo-2-pyridinyl)-2-cyano-n-[(1s)-1-phenylbutyl]-2-propenamide
degrasyn (wp1130)
S11144
AC-28415
DTXSID50459281
AKOS027301515
SW219459-1
wp1130(degrasyn)
S2243
BS-17736
mfcd18839228
CCG-206523
degrasyn; wp1130
EX-A2048
EN300-21040364
Z2312381828
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency4.15440.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency4.15440.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)IC50 (µMol)3.00003.00005.06676.8000AID761491
Ubiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)IC50 (µMol)3.00003.00004.45005.9000AID761493
Probable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)IC50 (µMol)4.62503.00004.62505.9000AID1069730; AID1411249; AID1622315; AID761492
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (73)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
male germ cell proliferationUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
response to ischemiaUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axon target recognitionUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
adult walking behaviorUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
regulation of macroautophagyUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axonal transport of mitochondrionUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
eating behaviorUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
negative regulation of MAP kinase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
positive regulation of glycolytic processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuromuscular processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
muscle cell developmentUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cellular response to xenobiotic stimulusUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
protein ubiquitinationUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
protein K48-linked deubiquitinationUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
neuron migrationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
DNA alkylation repairProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
chromosome segregationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
female gamete generationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein localizationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein import into peroxisome matrix, receptor recyclingProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein ubiquitinationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein deubiquitinationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
BMP signaling pathwayProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
positive regulation of protein bindingProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
monoubiquitinated protein deubiquitinationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
regulation of circadian rhythmProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
rhythmic processProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
axon extensionProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein stabilizationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cell divisionProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cilium assemblyProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cytosolic ciliogenesisProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein K63-linked deubiquitinationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein deubiquitination involved in ubiquitin-dependent protein catabolic processProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
positive regulation of TORC2 signalingProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
amyloid fibril formationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cell migrationProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
omega peptidase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
ubiquitin protein ligase bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
alpha-2A adrenergic receptor bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
ubiquitin bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
zinc ion bindingUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
ubiquitin bindingUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
cysteine-type endopeptidase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cysteine-type deubiquitinase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
protein bindingProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cysteine-type peptidase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
K63-linked deubiquitinase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
co-SMAD bindingProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
deubiquitinase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
molecular sequestering activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
K11-linked deubiquitinase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
K48-linked deubiquitinase activityProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
endoplasmic reticulum membraneUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuronal cell bodyUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuron projection terminusUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axon cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
lysosomeUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 5Homo sapiens (human)
cytoplasmProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
centrosomeProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cytosolProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cytoplasmProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
cytosolProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
ciliumProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
membraneProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
growth coneProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
nucleusProbable ubiquitin carboxyl-terminal hydrolase FAF-XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID632968Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.
AID1069729Inhibition of Usp9x in human Z138 cells using HA-Ub vinyl-sulfone as substrate at 1.25 to 5 uM after 4 hrs by immunoblotting analysis2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID761492Inhibition of USP9x in human Z138 cells after 1 hr by immunoblotting analysis2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Vialinin A is a ubiquitin-specific peptidase inhibitor.
AID761491Inhibition of UCH-L1 in human Z138 cells after 1 hr by immunoblotting analysis2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Vialinin A is a ubiquitin-specific peptidase inhibitor.
AID1069737Cytotoxicity against human MM1S cells after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID1069730Inhibition of human recombinant N-terminal His6-Smt3-fusion-tagged Usp9x catalytic domain expressed in Escherichia coli using Ub-AMC as substrate incubated for 30 mins prior to substrate addition by fluorescence assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID1574489Inhibition of recombinant His6-tagged USP7 catalytic domain (unknown origin) assessed as association constant using Ub-AMC as substrate by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
AID1069736Cytotoxicity against human A375 cells after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID632967Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.
AID1069735Cytotoxicity against human K562 cells after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID1069734Cytotoxicity against human Mino cells after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID1574490Inhibition of recombinant His6-tagged USP9x catalytic domain (unknown origin) assessed as association constant using Ub-AMC as substrate by fluorescence assay2019Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2
Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
AID761493Inhibition of USP5 in human Z138 cells after 1 hr by immunoblotting analysis2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Vialinin A is a ubiquitin-specific peptidase inhibitor.
AID1069738Cytotoxicity against human MM1S cells at 10 uM after 72 hrs by MTT assay2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).
AID632966Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Tyrphostin-like compounds with ubiquitin modulatory activity as possible therapeutic agents for multiple myeloma.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (5.41)29.6817
2010's29 (78.38)24.3611
2020's6 (16.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.52 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]